|
|
New Therapies for Pulmonary Arterial Hypertension: Orphan Drugs Seeking Opportunities in Wider Related IndicationsPublished by: Datamonitor Published: Jul. 24, 2002 - 52 Pages Table of ContentsEXECUTIVE SUMMARY INTRODUCTION What is PAH? Disease definition Diagnosis and classification The epidemiology of PAH WHY IS THE PAH MARKET ATTRACTING R&D INVESTMENT? High unmet need Orphan drug status THE CURRENT STATE OF THERAPY Non-pharmacological treatment Pharmacological treatment Non-PAH specific treatments Original PAH specific treatments Recently launched PAH specific treatments THE PAH PIPELINE Developmental treatments for PAH Iloprost Sitaxsentan (TBC-11252) Other developmental therapies COMPARATIVE ANALYSIS Drug delivery Target audience Cost of treatment Marketing potential Overall performance Conclusion REFERENCES General Associations and companies © Datamonitor 2002. All Rights Reserved. AbstractIntroduction: Pulmonary arterial hypertension (PAH) is a high value per patient niche market that until recently has been largely neglected in terms of the development of practical treatments. Several key advances over the past few months, including the launch of Tracleer and Remodulin, will play a major role in re-defining future treatment. With increasing awareness of the condition and several promising therapies in late stage development, treatment for PAH is set to enter a new era. Scope of this Report: * Comprehensive analysis of the attractiveness of the PAH market based on epidemiology, unmet needs, orphan drug incentives and potential revenue * In-depth profiles of current treatments, including PAH specific and non-PAH specific compounds * Analysis of clinical trial data and market potential of the recently launched PAH specific therapies and compounds in late stage development * Detailed comparative analysis of all PAH specific compounds in terms of efficacy, drug delivery, target audience and cost * Estimated potential of the PAH market and identification of opportunities of PAH specific drugs in wider related conditions. Report Highlights: PAH is a rare condition with an estimated 100,000 sufferers across the US and EU. However, despite the low patient population, this market has attracted R&D investment due to the high unmet need and high value per patient of treatment. Orphan drug status and the potential for expansion of specific therapies into wider indications will continue to provide further investment incentives. Tracleer (bosentan) is the most promising PAH compound, although along with beraprost, it has had disappointing trial results in additional indications. In the future, new second generation endothelin receptor antagonists may offer superior benefits in both PAH and additional indications. Key Reasons to Buy this Report: * Assess the attractiveness of the PAH market for R&D investment and/or in-licensing activity * Identify strengths, weaknesses, opportunities and threats of recently launched and late stage developmental therapies * Identify opportunities and strategies for PAH specific compounds to be developed for additional indicationsGet Full Details About This Report >> |
|
|||
|
About MarketResearch.com
|
||||